Results 201 to 210 of about 1,085,002 (240)
Some of the next articles are maybe not open access.
Regenerative Cell and Tissue-based Therapies for Pulmonary Arterial Hypertension
Canadian Journal of Cardiology, 2014Within the span of 2 decades, cell-based regenerative therapies for pulmonary arterial hypertension have progressed from bench-side hypotheses to clinical realities. Promising preclinical investigations that examined the therapeutic potential of endothelial progenitor cell and mesenchymal stem cell populations have demonstrated the safety and efficacy ...
William S, Foster +2 more
openaire +2 more sources
The therapeutic potential of mesenchymal stem cells
Expert Opinion on Biological Therapy, 2007Mesenchymal stem cells (MSCs) are multipotent cells with a number of potential therapeutic applications. At present, they are being used in a clinical trial for the treatment of myocardial infarction and are being studied as a therapy for other vascular disorders.
Sonia C, Picinich +4 more
openaire +2 more sources
Changes in dendritic cell function in the immune response to sepsis
Expert Opinion on Biological Therapy, 2007Sepsis represents a complex clinical syndrome of significant morbidity and mortality. This continues to be the case in intensive care units around the world, despite extensive use of antibiotics, aggressive surgical intervention and optimization of nutritional support.
Xin, Huang +4 more
openaire +2 more sources
Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea
Tissue Engineering Part A, 2015Extensive investment on research and development of cell therapy products (CTPs) and tissue-engineered products (TEPs) has been made in Korea, and various commercial products are born in market. The Ministry of Food and Drug Safety (MFDS) in Korea regulates CTPs and TEPs as biological products under the authority of the Pharmaceutical Affairs Act.
openaire +2 more sources
Regulatory Framework for Cell and Tissue Based Therapies in Europe
2016Whereas some basic therapies based on tissues and cells have been in clinical use for years, advances in regenerative medicine present new challenges and new types of products for regulation. This article focuses on cell therapies which can be classified as medicinal products across the European Union.
Gudrun Tiedemann, Sebastian Sethe
openaire +1 more source